基于无机纳米粒子的药物输送系统用于神经退行性疾病的治疗疗法
Iman Bagherpour1,2, M R Mozafari1, Seyed Morteza Naghib3
1Australasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton, VIC 3168, Australia.
Current pharmaceutical design
|February 12, 2025
概括
纳米技术提供了先进的药物递送系统 (NDDS),使用纳米粒子治疗神经退行性疾病 (NDs). 这些系统有效地穿越血脑屏障 (BBB),以改善诊断和治疗,并减少副作用.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
背景情况:
- 神经退行性疾病 (NDs) 在老年人群中很常见,影响中枢和外围神经系统.
- 神经退行包括渐进的神经元损失,可能导致细胞死亡.
- 血脑屏障 (BBB) 对于维持大脑平衡至关重要,但它阻碍了药物输送.
研究的目的:
- 探索基于纳米技术的药物输送系统 (NDDS) 在管理神经退行性疾病中的作用.
- 突出纳米颗粒 (NP) 的潜力,提高NDs的诊断和治疗疗效.
- 审查克服BBB的策略,以改善大脑中的药物生物可用性.
主要方法:
- 开发各种纳米粒子 (NP) 使用生物相容材料,如多糖,聚合物,,黄金,蛋白质和加多.
- 利用基于纳米技术的方法来促进跨越BBB的药物运输.
- 在临床前和临床研究中研究各种NP配方的治疗益处.
主要成果:
- 基于纳米粒子的药物递送系统 (NDDS) 对神经退行性疾病具有显著的治疗益处.
- 各种生物相容的纳米粒子在诊断和药物输送中表现出有效性.
- 纳米技术提供了提高BBB药物透率的策略,增加了大脑药物的生物可用性.
结论:
- 对于神经退行性疾病的诊断和治疗,NDDS具有巨大的前景.
- 在利用纳米技术实现向药物输送和改善治疗结果方面存在机遇.
- 在NDDS的开发和临床应用方面仍然存在挑战,需要进一步研究.
相关概念视频
01:15Parkinson's Disease: Overview
436
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
436
01:29Drug Delivery: Parenteral Route
378
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
378
01:22Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155
01:24Parkinson's Disease: Treatment
189
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
189